KPV
Lysine-Proline-Valine (α-MSH C-terminal)
KPV (Lysine-Proline-Valine (α-MSH C-terminal)) is a healing & recovery research compound. Anti-inflammatory tripeptide from α-MSH — calms NF-κB signaling systemically and in the gut.
KPV quick facts
| Reported research dose | Inj: 250mcg-2mg · Oral: 500mcg-1mg |
| Route | Subq |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | Short (mins-hrs) |
| Forms | Injectable, Oral |
| Evidence level | Animal + anecdotal |
Gut and skin inflammation favorite. Pairs naturally with BPC-157 for the gut.
How KPV works
Anti-inflammatory tripeptide from α-MSH — calms NF-κB signaling systemically and in the gut.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Where to get KPV
KPV is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for KPV
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- Alpha-MSH, the parent hormone KPV is the C-terminal fragment of, has been studied in humans for inflammatory conditions. KPV itself is used orally for gut inflammation and topically for skin, with a reported profile of being quietly effective and almost entirely without side effects — which is consistent with a fragment that lacks the parent's receptor activity.
🧪 How the mechanism reads
- The tripeptide carries alpha-MSH's anti-inflammatory action without its melanocortin receptor binding — so it is predicted to calm inflammation without the pigmentation, flushing or erectile effects the full hormone causes. That separation is the entire reason to use the fragment.
- Rodent colitis models show reduced inflammatory markers with oral dosing, and the mechanism (NF-κB inhibition in gut epithelium) is why oral delivery makes sense here when it would not for most peptides.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What KPV actually does
KPV is Lys-Pro-Val, residues 11–13 of alpha-melanocyte-stimulating hormone — the last three amino acids of the hormone, and nothing else. 342.4 Da as the free acid, formula C16H30N4O4. The lysine side chain is the only ionizable group besides the termini and there is no acidic residue at all, so the computed isoelectric point is 9.7 and the net charge is about +0.9 at blood pH. This peptide never reaches electrical neutrality anywhere in the body, which is unusual for something this small and matters for how it partitions.
The identity question no label answers. In the parent hormone the valine is amidated — alpha-MSH ends in Val-NH2. Research KPV is usually sold as the free acid. And the published antimicrobial work used Ac-Lys-Pro-Val-NH2, capped at both ends Charnley 2008. That is three different molecules circulating under one name, differing by a full unit of charge at the C-terminus, and the papers do not all use the same one. No vendor publishes which they ship.
It has no receptor, and that is the point rather than a gap. The melanocortin recognition motif is His-Phe-Arg-Trp Getting 2003; KPV contains none of those four residues, and the review literature states plainly that it lacks the entire sequence motif required to bind known melanocortin receptors while retaining almost all of the parent hormone's anti-inflammatory capacity and none of its pigmentary action Brzoska 2010. This was tested rather than assumed: KPV's anti-migratory effect was not blocked by the MC3/MC4 antagonist SHU9119, KPV failed to raise cAMP where the receptor agonist MTII did, and KPV still worked in recessive yellow (e/e) mice whose MC1 receptor is non-functional Getting 2003. In colitis the same e/e test was repeated and KPV rescued every animal in the treatment group from death Kannengiesser 2008.
The mechanism is a transporter, and it is named: PepT1. PepT1 (SLC15A1) is the proton-coupled di- and tripeptide transporter of the small intestine, and it is induced in the colon during inflammatory bowel disease — normally it is barely there. Uptake of tritiated KPV was measured directly, with cold KPV competing against a radiolabelled PepT1 substrate, in Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and in Jurkat T cells; once inside, nanomolar KPV inhibited NF-kappaB and MAP kinase signaling and cut pro-inflammatory cytokine secretion Dalmasso 2008. That is a complete mechanism at molecular resolution: a named carrier, a measured uptake, an intracellular target and a functional readout — which is more than almost anything else in this catalog has.
Why three residues is the whole design. PepT1 carries di- and tripeptides. At exactly 3 residues KPV is inside that substrate range; a tetrapeptide is not. The peptide is short enough to use the gut's own transporter, and the transporter is upregulated precisely in the tissue the peptide is meant to treat. That is a delivery system that concentrates the drug where the disease is, and it is the single most interesting fact about this molecule.
Cell, rodent, human — and where it stops
In cells, including the negative result. Nanomolar concentrations of KPV suppressed NF-kappaB activation by luciferase reporter, blocked MAP kinase signaling by western blot, and reduced cytokine output by ELISA and real-time RT-PCR, in two human epithelial lines and in a human T cell line Dalmasso 2008. Against that: in an activated macrophage assay, KPV failed to inhibit KC and IL-1beta release, while alpha-MSH and MTII both did Getting 2003. The cell-level effect is therefore not universal across cell types, and the page that only quotes the first paper is quoting half the literature.
In rodents. Oral KPV in drinking water reduced the incidence and cytokine expression of both DSS-induced and TNBS-induced colitis in mice Dalmasso 2008. In DSS colitis and in CD45RB-high transfer colitis, KPV produced earlier recovery, stronger body-weight regain, fewer inflammatory infiltrates on histology and lower colonic myeloperoxidase activity Kannengiesser 2008. Systemically, in crystal-induced peritonitis, KPV cut neutrophil accumulation in the peritoneal cavity, and it worked in IL-1beta-induced peritonitis too Getting 2003. And in the most technically advanced version, KPV was loaded into hyaluronic-acid-functionalized polymeric nanoparticles of about 272.3 nm with a zeta potential near −5.3 mV, delivered orally inside a chitosan/alginate hydrogel, and outperformed non-targeted particles at healing mucosa and lowering TNF-alpha Xiao 2017.
In humans: zero. There is no clinical trial of KPV of any size, phase or country. What exists in people is the parent hormone class, reviewed alongside KPV rather than tested as KPV Brzoska 2010.
The obstacles, and the biggest one is hiding inside the best paper.
- The nanoparticle result argues against plain oral KPV. The entire reason Xiao's group built a hyaluronic-acid-targeted, hydrogel-protected particle is that free peptide does not arrive in the colon in useful quantity or stay where it is needed Xiao 2017. A capsule of loose KPV powder is not the experiment that worked; it is the control arm that the targeted formulation beat.
- Drinking-water dosing is an exposure, not a dose. The colitis results that everyone quotes were produced by putting peptide in the water supply Dalmasso 2008, so each animal's intake tracked its thirst. No mg/kg equivalent for a person can be derived from that, and the 500 µg–1 mg oral figure used in practice is not scaled from it.
- The route on offer discards the mechanism. Every gut result is oral and runs through an intestinal transporter. A subcutaneous injection bypasses PepT1 entirely. For a gut indication that is the opposite of an upgrade, and it is the reverse of the usual assumption that injecting is stronger.
- The molecule mismatch. Free acid, C-terminal amide and doubly-capped Ac-KPV-NH2 are three different compounds and the literature uses more than one of them Charnley 2008.
- Every endpoint is a rodent endpoint. Colitis score, myeloperoxidase, cytokine mRNA, histological infiltrate. Not one human-measurable outcome appears anywhere in the record — not even fecal calprotectin, which would have been trivial to add.
KPV pharmacokinetics — how much of it actually gets in
What degrades it. A free tripeptide with an unblocked N-terminus is a substrate for aminopeptidases, which are abundant on vascular endothelium and on the intestinal brush border. There is no published plasma pharmacokinetic study of KPV in any species in the indexed literature reachable for this page — no half-life, no Cmax, no AUC — so the honest statement is that the residence time is expected to be minutes and has never been measured.
The oral barrier, and the one compound here that partly beats it. Almost every peptide on this site fails orally for the same three reasons: acid, proteases, and no way across the enterocyte. KPV has an answer to the third. PepT1 carries di- and tripeptides across the intestinal epithelium, KPV is a tripeptide, and its carrier-mediated uptake was demonstrated with a radiolabelled competition assay rather than assumed Dalmasso 2008. That is a measured route in. What it is not is proof of systemic bioavailability: PepT1 delivers into the enterocyte, which is where the anti-inflammatory action is wanted, and no plasma concentration after an oral dose has ever been published.
The numbers that do exist. 3 residues; 342.4 Da; net charge about +0.9 at pH 7.4; activity at nanomolar concentrations in cells Dalmasso 2008; 272.3 nm particles when the peptide has to be protected to reach the colon Xiao 2017.
The injectable comparator, stated against the grain. Subcutaneous injection removes the gut, the acid and the first-pass liver. It also removes the only delivery mechanism this compound has direct measurement behind, and it removes the selectivity that comes from PepT1 being induced in inflamed colon. For a systemic or skin indication injection is defensible; for a gut indication the mechanism argues for the oral route, and this is one of the few pages on this site where that is true.
What would have to be true, and how you would know it was not
Four predictions, and the fourth is a route experiment anyone running both forms can do.
1. High-sensitivity CRP falls only if it was raised. The mechanism is suppression of NF-kappaB signaling Dalmasso 2008, so the effect has to act on inflammation that is actually running. Draw it at baseline and at 4–8 weeks. In someone whose baseline is already low, predict no change — and a large subjective effect with an unchanged normal CRP is a symptom report, not the published mechanism.
2. Fecal calprotectin is the readout with the strongest mechanistic case, and nobody runs it. Every rodent result is a colonic inflammation result. Calprotectin is a cheap stool test, it maps onto exactly the tissue the mechanism claims, and it moves fast enough to see over 6–8 weeks. If a gut-directed course does not move it, the compound is not doing in a human what it did in the mouse.
3. A CBC and ferritin will not move, which is the prediction that argues against the product. No mechanism connects a tripeptide to hemoglobin, white cell count or iron stores. Two caveats make the draw worth doing anyway: in inflammatory gut disease a rising hemoglobin and a falling platelet count would be genuine improvement, and ferritin is an acute-phase reactant that falls when inflammation settles rather than when iron improves. Interpreting either without the CRP alongside is how people mislead themselves.
4. The route prediction, which is falsifiable and cuts against the injectable. If the gut effect is PepT1-mediated, then for a gut endpoint the oral route should be at least as good as the injectable one at the same dose. Almost everyone assumes the opposite. Anyone with access to both forms and a calprotectin test can run a within-person crossover and produce the first data that exists on the question.
What nobody has tested yet
Six unrun experiments. The first is a single mass-spec run and it would change what half the market is buying.
1. Which KPV is in the vial. Free acid, C-terminal amide, or the doubly-capped Ac-Lys-Pro-Val-NH2 used in the antimicrobial work Charnley 2008? These differ in charge and in protease susceptibility, no vendor states which they sell, and one LC-MS run per batch would settle it permanently.
2. A plasma concentration in a person, after any dose, by any route. It has never been published. Every dosing recommendation for this compound, including this site's, rests on rodent exposure that was itself delivered in drinking water.
3. Fecal calprotectin before and after an oral course. Ten people, two stool tests each, and the result would be the first human efficacy data of any kind for KPV. Nothing about it requires a laboratory or a grant.
4. Does PepT1 expression predict who responds? The transporter is induced in inflamed colon Dalmasso 2008, so the mechanism predicts that the more inflamed the tissue, the better the delivery — a dose-response that runs backwards from every other drug. It is testable in a biopsy series and has never been tested.
5. Oral against injectable, head to head, gut endpoint. The single comparison the mechanism makes a directional prediction about, and no one has run it in any species.
6. The antimicrobial arm has been abandoned for fifteen years. Melanocortin tripeptides were active against both Staphylococcus aureus and Escherichia coli, and — the detail that matters for design — the lysine's positive charge was not required, since Ac-Ala-Pro-D-Val-NH2 worked too Charnley 2008. A tripeptide that is simultaneously anti-inflammatory and antibacterial is an obvious topical candidate for infected inflammatory skin, and no clinical study of any kind has followed.
KPV — its own safety story, not its class's
The class block on this page is the repair-peptide one, and its central warning is about angiogenesis — new vessel growth as the shared mechanism of the healing peptides. KPV is not an angiogenic compound. It is not a growth-factor mimic, it does not signal through a growth-factor receptor, and the tumor-angiogenesis reasoning that applies to BPC-157 or TB-500 does not transfer to it. Its own risk story is different and more specific.
1. The real mechanism-derived risk is immune suppression at the signaling level, in T cells. KPV is taken up by PepT1 in Jurkat T cells as well as epithelium, and inside the cell it suppresses NF-kappaB and MAP kinase signaling Dalmasso 2008. NF-kappaB is the master switch of the innate inflammatory response. Anything that blunts it blunts the response you need during an infection and, in principle, the response to a vaccination. That is the concern this page should carry, and it is nowhere on the class block.
2. The counterweight is real and it is in the same literature. Melanocortin tripeptides have direct antibacterial activity against Gram-positive and Gram-negative organisms Charnley 2008, so an anti-inflammatory that is also mildly antibacterial does not carry the same infection risk as a steroid. Both facts are true and neither has been tested in a person with an infection.
3. Identity is a safety issue here, not a purity issue. Free acid against C-terminal amide is a one-unit charge difference on a three-residue molecule — proportionally the largest structural ambiguity of any compound in this cohort — and the published papers do not all use the same form Charnley 2008.
4. What zero human data actually means. Not one trial of any size has been run Brzoska 2010. Every statement about tolerability, including the widely repeated one that KPV is quietly effective and almost without side effects, is a collection of reports with no denominator. In a compound used for months at a time by people with active inflammatory bowel disease — who have an alternative with actual trials — the substitution risk is the one that matters: an untreated flare damages bowel, and the cost of a peptide course is the weeks it takes.
Sources read for this page
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008 · PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases 2008 · PMID 18092346
- Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics 2003 · PMID 12750433
- Charnley M, et al. Anti-microbial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence in Gram-positive and Gram-negative bacteria. Peptides 2008 · PMID 18355945
- Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology 2010 · PMID 21222263
- Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 2017 · PMID 28143741
KPV — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
KPV — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What KPV moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Reconstitution maths — the calculator
- Needle gauge and injection site
- Storage and travel
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — KPV in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside KPV
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | The anti-inflammatory claim, and the thing separating IBD from IBS |
| Complete Blood Count (CBC) with Differential | Anemia is the commonest sign of an inflamed gut |
| Ferritin | The first thing a damaged gut stops absorbing |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and albumin — albumin falls in real gut inflammation |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
What it is, why it recurs, and where this fits — free to read.
KPV — frequently asked questions
What is KPV?
KPV (Lysine-Proline-Valine (α-MSH C-terminal)) is a healing & recovery research compound. Anti-inflammatory tripeptide from α-MSH — calms NF-κB signaling systemically and in the gut.
Is the full KPV protocol on this page?
The reported research dose is on this page, along with how KPV works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of KPV?
KPV has an approximate half-life of Short (mins-hrs), which is part of what determines how often it's dosed.
What forms does KPV come in?
KPV is available as: Injectable, Oral.
What's the evidence behind KPV?
Current evidence level: Animal + anecdotal. KPV is offered for research purposes only and is not an approved medicine.
KPV inside a finished plan
One arm of 4 Protocol Blueprints, free to read in full.
What KPV is used for
KPV appears under 5 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
KPV is the inflammation-resolution arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.